Save the date: the FDA will hold an advisory committee meeting to review Lykos Therapeutics’ New Drug Application (NDA) for MDMA-assisted psychotherapy in the treatment of PTSD on
Save the date: the FDA will hold an advisory committee meeting to review Lykos Therapeutics’ New Drug Application (NDA) for MDMA-assisted psychotherapy in the treatment of PTSD on
Reunion Neuroscience, a New Jersey biotech that spun out from the ill-fated ketamine clinic chain Field Trip Health two years ago, has announced a $103m Series A
General Overview First Look at Nolan Williams et al.’s Ibogaine IP: Is Co-Administration of Magnesium and Ibogaine Common Practice? Clexio Biosciences Protects CLE-100 Development Programs
We are a group of clinical investigators, clinicians, supervisors, trainers, and medical monitors who worked on the Phase 3 clinical trials of MDMA-Assisted Psychotherapy (MDMA-AP)
A. License Types, Qualifications, Procedures, and Financial Interests The Natural Medicine Division’s first set of draft rules focuses on the overall licensing framework for Natural
Featured content in this Issue: EQUULUS Therapeutics Emerges from Stealth with Non-Hallucinogenic Ibogaine Analog as Lead Candidate Responses to ICER’s Draft Evidence Report on MDMA-Assisted
On Tuesday the 16th and Wednesday the 17th of April, the European Medicines Agency (EMA) hosted a meeting in Amsterdam, “Multi-stakeholder workshop on psychedelics – Towards an
Featured content in this Issue: Numinus’ Shifting Focus Toward U.S. Market Revealed via “Unauthorized Disclosure” An “Unauthorized Disclosure” “Canadian Reorganization” “Cost Containment Initiatives” Algernon Pharmaceuticals
Psychedelic Alpha’s Josh Hardman sits down with Jaskaran (‘Jaz’) Singh, Vice President Psychiatry Development at Neurocrine Biosciences. For the purposes of this conversation, however, we focus on